FindTrial
Sign In

Genomic biomarker research for advanced pancreatic cancer and neuroendocrine tumor.

Genomic biomarker research for advanced pancreatic cancer and neuroendocrine tumor. - Genomic biomarker research for advanced pancreatic cancer and neuroendocrine tumor.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000022960
Enrollment
230
Registered
2016-06-30
Start date
2008-11-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer, pancreatic neuroendocrine tumor

Interventions

None listed

Sponsors

Chiba Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with pancreatic cancer or pancreatic neuroendocrine tumor. 2) Patients with unresectable or recurrunt disease. 3) Patients who are planned to undergo a biopsy. 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Bleeding tendency 2) Patients who are judged to be inappropriate for the study participatin by the primary physician

Design outcomes

Primary

MeasureTime frame
Comprehensive genomic analysis compared with clinical information (e.g. response to chemotherapy, survival outcome, or clinical stage).—

Countries

Japan

Contacts

Public ContactKentaro Sudo

Chiba Cancer Center Gastroenterology

ksudo@chiba-cc.jp043-264-5431

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026